Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
11β-MNTDC for Male Contraception (CCN014)
NCT02754687Phase 1Completed
- Sponsor
- Premier Research
- Start
- Jul 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in male contraception comparing Placebo Arm with 11β-MNTDC Arm (2 arms). Primary endpoints: Safety and tolerability as measured by adverse events, Safety and tolerability as measured by changes from baseline in vital signs and 3 more. Started Jul 2016; status: completed.
02
Drugs
11β-methyl nortestosterone dodecylcarbonate
03
Conditions
male contraception
Beyond the preview
Go deeper on NCT02754687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02754687.